Visual fields and tiagabine: A quandary

Seizure

Volumn 10, Issue 7, 2001, Pages 525-529

  Kaufman, Kenneth R ^a   Lepore, Frederick E ^a   Keyser, Bruce J ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Adverse effects; Antiepileptic drugs; Bipolar disorder; Carbamazepine; Epilepsy; GABA; Goldmann perimetry; Hymphrey perimetry; Psychiatry; Tiagabine; Topiramate; Treatment; Vigabatrin; Visual field defects

Indexed keywords

4 AMINOBUTYRIC ACID; ALLOPURINOL; AMILORIDE; ANTICONVULSIVE AGENT; ATORVASTATIN; BECLOMETASONE DIPROPIONATE; BENZATROPINE; CARBAMAZEPINE; CLONAZEPAM; FENOFIBRATE; GABAPENTIN; HYDROCHLOROTHIAZIDE; LAMOTRIGINE; LISINOPRIL; LITHIUM; LORATADINE; MELATONIN; OLANZAPINE; PAROXETINE; PERPHENAZINE; RANITIDINE; ROFECOXIB; SALBUTAMOL; TETRAHYDROLIPSTATIN; TIAGABINE; TOPIRAMATE; TRAMADOL; TRAZODONE; VIGABATRIN;

ADULT; ARTICLE; ATAXIA; CASE REPORT; CONFUSION; DEPRESSION; DRUG EFFECT; DRUG WITHDRAWAL; GABAERGIC SYSTEM; HUMAN; MALE; MANIC DEPRESSIVE PSYCHOSIS; MENTAL PATIENT; MOTOR DYSFUNCTION; PRIORITY JOURNAL; SLEEP DEPRIVATION; SYMPTOM; VISUAL FIELD DEFECT;

EID: 0035689773     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1053/seiz.2001.0543     Document Type: Article

References (41)

1. Severe persistent visual field constriction associated with vigabatrin
2. Visual dysfunction in patients receiving vigabatrin: Clinical and electrophysiologic findings
3. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects
4. Visual field defects in patients taking vigabatrin
5. A controlled study of vigabatrin and visual abnormalities
6. Visual field defects associated with vigabatrin therapy
7. Electrooculography, electroretinography, visual evoked potentials, and multifocal electrotinography in patients with vigabatrin-attributed visual field constriction
8. Reversibility of vigabatrin-induced visual-field defect
9. Recovery of visual field constriction following discontinuation of vigabatrin
10. Visual function loss from vigabatrin: Effect of stopping the drug
11. Audiogenic seizure protection by elevated brain GABA concentration in mice: Effects of gamma-acetylenic GABA and gamma-vinyl GABA, two irreversible GABA-T inhibitors
12. Effects of tiagabine and vigabatrin on GABA uptake into primary cultures of rat cortical astrocytes
13. Vigabatrin-associated retinal cone system dysfunction: Electroretinogram and ophthalmologic findings
14. Symptomatic and asymptomatic visual loss in patients taking vigabatrin
15. Diazepam and its effects on visual fields
16. Severe visual-field constriction and side-effects of GABA-mimetic antiepileptic drugs
17. Concentric changes in the visual field associated with GABA-mimetic antiepileptic agents
18. Severe persistent visual field constriction associated with vigabatrin. Patients taking vigabatrin should have regular visual field testing
19. Using the electroretinogram to detect and monitor the retinal toxicity of anticonvulsants
20. Open-label adjunctive topiramate in the treatment of bipolar disorders
21. Gabapentin use in neuropathic pain syndromes
22. Open maintenance treatment of bipolar spectrum patients who responded to gabapentin augmentation in the acute phase of treatment
23. Adjunctive tiagabine treatment of psychiatric disorders: Three cases
24. Tiagabine
25. Vigabatrin and tiagabine are pharmacologically different drugs. A pre-clinical study
26. Absence of visual field defects in patients taking tiagabine
27. Visual field restriction with new antiepileptic medication
28. Predictability of visual field defects in patients exposed to GABAergic agents, vigabatrin, or tiagabine
29. Absence of concentric visual field defects in patients with long-term tiagabine monotherapy
30. Lamotrigine and toxic epidermal necrolysis
31. Lamotrigine toxicity secondary to sertraline
32. Assessment of colour vision in epileptic patients exposed to single-drug therapy
33. Color vision in epileptic patients treated with vigabatrin or carbamazepine monotherapy
34. Automated perimetry detects visual field loss before manual Goldmann perimetry
35. Characteristics of a unique visual field defect attributed to vigabatrin
36. Separating the retinal electrophysiologic effects of vigabatrin. Treatment versus field loss
37. Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication
38. Severe persistent visual field constriction associated with vigabatrin. Reaction may be dose dependent
39. Visual field defect associated with vigabatrin: Method of estimating prevalence was inappropriate
40. Visual field defect associated with vigabatrin: Observational cohort study